Results from the trial showed that Lynparza in combination with abiraterone plus prednisone significantly improved radiographic progression-free survival versus abiraterone plus prednisone, a standard of care, as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair gene mutations.
Globally, prostate cancer is the second most common cancer in patients assigned male at birth, with an estimated 1.4m patients diagnosed worldwide in 2020.
Approximately 10-20% of patients with advanced prostate cancer are estimated to develop CRPC within five years, and at least 84% of these patients may develop metastases at the time of CRPC diagnosis.
Patients with advanced prostate cancer have a particularly poor prognosis, and the five-year survival rate remains low.
In September 2021, at a planned interim analysis, the independent Data Monitoring Committee concluded that the PROpel trial met its primary endpoint of rPFS.
The results were presented in February 2022 at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, and additional data on safety and tolerability as well as pharmacokinetics were presented at the 2022 ASCO annual meeting on June 6.
As previously reported, in the Phase 3 PROpel trial, Lynparza in combination with abiraterone plus prednisone (n=399) reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886